NCT06090305 - Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex) | Biotech Hunter

Enrollment

470

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

December 6, 2024

Study Completion Date

December 6, 2024

Conditions

Multiple Sclerosis

Interventions

BEHAVIORAL

levidex

Participants will receive access to the digital health application levidex in addition to treatment as usual (TAU).

BEHAVIORAL

Control

Participants will receive access to an overview of relevant brochures from the Deutsche Multiple Sklerose Gesellschaft (German Multiple Sclerosis Society) on the topic of lifestyle in MS in addition to treatment as usual (TAU).

OTHER

treatment as usual (TAU)

Trial Locations (1)

22085

GAIA AG, Hamburg

All Listed Sponsors

collaborator

University Hospital Schleswig-Holstein

OTHER

collaborator

Universität Duisburg-Essen

OTHER

lead

Gaia AG

INDUSTRY